Abstract: A simulation system includes at least one processor configured to execute a computer program product, stored upon a storage medium. The computer program product includes a database application, a process simulation application, and an integration tool, where the database application and the process simulation application are discrete, stand alone products. The process simulation application can simulate industry processes using at least one flowsheet, which models a general flow of industry processes. The integration tool can map process simulation application objects and properties to database application objects, can convey information between mapped objects, can perform case management functions, and can perform orchestrated calculation functions.

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Abstract: Compounds disclosed herein including compounds of formula I?: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

Abstract: The invention features devices and methods for the deterministic separation of particles. Exemplary methods include the enrichment of a sample in a desired particle or the alteration of a desired particle in the device. The devices and methods are advantageously employed to enrich for rare cells, e.g., fetal cells, present in a sample, e.g., maternal blood and rare cell components, e.g., fetal cell nuclei. The invention further provides a method for preferentially lysing cells of interest in a sample, e.g., to extract clinical information from a cellular component, e.g., a nucleus, of the cells of interest. In general, the method employs differential lysis between the cells of interest and other cells (e.g., other nucleated cells) in the sample.

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: Disclosed in the present invention are a method for preparing tealeaf extracts having different tastes, and a beverage prepared using extracts made by the method. The method involves adding tealeaves to an extraction column, performing continuous extraction using water at 5° C.-140° C. at a flow rate of 20-200 mL/min, collecting liquid extracts in sections, and drawing a relative taste intensity curve; and according to a taste variation shown in the relative taste intensity curve, recombining collected liquid extracts of different sections. The method of the present invention can produce tealeaf extracts having high grade taste and high concentration without the need for a concentration step, the extraction yield is high, and the sensory attributes of the tealeaf extracts can be rebalanced in a very flexible manner, so as to obtain beverages of different tastes.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Abstract: A device including a water chamber for filtering smoke or vapor prior to inhalation of the smoke or vapor. The device including a vaporization chamber that contains a substance to be heated or burned. The device including an air flow chamber, herein the air flow chamber connects the vaporization chamber, wherein the air flow chamber is configured to provide a tunnel between an upper edge and a lower edge of the air flow chamber, for passage of air/vapor from an air/vapor entry port to a filtered air exit port for air/vapor at the water chamber, in a snake like manner; wherein the air/vapor entry port is located at a point where the vaporization chamber is joined to the water chamber.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: A device having a first chamber for filtering smoke or vapor prior to inhalation of the smoke or vapor. A second chamber contains a substance to be heated or burned. A heating or burning plate is configured to heat or burn the contained substance to produce the smoke or vapor and a stirring component is configured for stirring and redistributing the substance while being heated or burned. A one-way valve passes the smoke or vapor in one direction, from the second chamber to the first chamber and prevent leakage of the smoke or vapor within the first chamber.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: A system for a dynamically evolving cognitive architecture for the development of a secure key and confidence level based data derived from biometric sensors and a user's behavioral activities. The system comprises one or more processors, one or more sensors, one or more databases, and non-transitory computer readable memory. The non-transitory computer readable memory comprises a plurality of executable instructions wherein the instructions, when executed by the one or more processors, cause the one or more processors to process operations comprising creating a set of policies based on user data sets and inputs, creating a faceted classification, establishing a Trust Level, processing sensor data, comparing data to one or more databases, correlating data, updating Trust Levels, updating security keys, and storing the keys in memory. In certain embodiments, the stored data is used to create a usage schema independent from a user's actual identity.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Abstract: Methods, systems and computer readable media for quality of service aware hybrid multicast networks are described. A method can include receiving a request for content from a first receiver and initiating a quality of service aware hybrid tree construction by sending a multicast service level specification message to a first overlay tree manager. The method can also include dividing the tree at the overlay tree manager and communicating with other overlay tree managers in the network. The method can further include computing, at each overlay tree manager, a shortest path tree using a constrained algorithm and sending, from each overlay tree manager, a message to each IP manager in the network requesting that the IP managers construct an IP multicast tree and install the tree on one or more corresponding routers. The method can also include enforcing multicast routes and quality of service on the one or more routers.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: The invention features devices and methods for the deterministic separation of particles. Exemplary methods include the enrichment of a sample in a desired particle or the alteration of a desired particle in the device. The devices and methods are advantageously employed to enrich for rare cells, e.g., fetal cells, present in a sample, e.g., maternal blood and rare cell components, e.g., fetal cell nuclei. The invention further provides a method for preferentially lysing cells of interest in a sample, e.g., to extract clinical information from a cellular component, e.g., a nucleus, of the cells of interest. In general, the method employs differential lysis between the cells of interest and other cells (e.g., other nucleated cells) in the sample.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Abstract: Method and systems for manufacturing a tablet comprising an electronic device are disclosed. In one method, a powdered material is provided into a die cavity of a tablet press and an electronic device is dispensed from a tape-and-reel carrier tape operatively coupled to the tablet press into the die cavity. The powdered material and the electronic device are compressing to form a tablet. A system comprises a tablet press comprising a die cavity for receiving a powdered material and an electronic device therein, an upper punch, and a lower punch. The upper and lower punches are operative to form the powdered material and the electronic device into a tablet. A tape-and-reel carrier tape is operatively coupled to the tablet press, where the carrier tape is configured for holding the electronic device. A transfer mechanism is used to transfer the electronic device from the tape carrier to the die cavity.